IFP Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-52
Closed -$37.8K 3567
2023
Q1
$37.8K Sell
52
-63
-55% -$6K ﹤0.01% 1713
2022
Q4
$84K Buy
115
+23
+25% +$3.33K ﹤0.01% 1861
2022
Q3
$67K Buy
92
+29
+46% +$8.42K ﹤0.01% 2158
2022
Q2
$46K Hold
63
﹤0.01% 2217
2022
Q1
$46K Buy
+63
New +$8.09K ﹤0.01% 2217
2021
Q4
Sell
-1
Closed -$1K 3488
2021
Q3
$1K Buy
+1
New +$306 ﹤0.01% 3131
2021
Q2
Sell
-7
Closed -$3.27K 3228
2021
Q1
$4K Buy
+7
New +$4.36K ﹤0.01% 2499
2019
Q4
Sell
-25
Closed -$17.2K 3105
2019
Q3
$16K Buy
+25
New +$19.8K ﹤0.01% 1865
2019
Q1
Sell
-1
Closed 3326
2018
Q4
$0 Sell
1
-17
-94% -$6.72K ﹤0.01% 3850
2018
Q3
$9K Sell
18
-1
-5% -$429 ﹤0.01% 2920
2018
Q2
$9K Buy
19
+2
+12% +$1.27K ﹤0.01% 2977
2018
Q1
$11K Hold
17
﹤0.01% 2744
2017
Q4
$11K Hold
17
﹤0.01% 2783
2017
Q3
$16K Sell
17
-9
-35% -$7.99K ﹤0.01% 2762
2017
Q2
$24K Hold
26
﹤0.01% 2477
2017
Q1
$25K Sell
26
-1
-4% -$931 ﹤0.01% 2361
2016
Q4
$22K Hold
27
﹤0.01% 2395
2016
Q3
$23K Sell
27
-14
-34% -$11.3K ﹤0.01% 2323
2016
Q2
$34K Buy
+41
New +$44.6K ﹤0.01% 1998
2016
Q1
Sell
-8
Closed -$10K 3334
2015
Q4
$10K Buy
+8
New +$13.2K ﹤0.01% 2591

Other funds holding TCRT

IFP Advisors's TCRT Position: Q2 2023 in Review

IFP Advisors sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 52 shares — an estimated $37.8K sold.

IFP Advisors first reported a position in TCRT in Q4 2015 and held it in 20 quarters. The position peaked at $84K in Q4 2022. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

  • IFP Advisors reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • IFP Advisors sold 52 Alaunos Therapeutics shares in Q2 2023, an estimated $37.8K.
  • IFP Advisors first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 20 quarters.
  • IFP Advisors's Alaunos Therapeutics position peaked at $84K in Q4 2022.
  • 100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on IFP Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.